Stay updated on Risankizumab in PsA Patients: Clinical Trial
Sign up to get notified when there's something new on the Risankizumab in PsA Patients: Clinical Trial page.

Latest updates to the Risankizumab in PsA Patients: Clinical Trial page
- Check6 days agoChange DetectedRevision updated to v3.0.2 and the Back to Top element was removed; core content, pricing, stock, and time-slot information remain unchanged.SummaryDifference0.1%
- Check13 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%
- Check20 days agoChange DetectedThe webpage has undergone significant updates, including the addition of numerous facility names and locations across various countries, as well as new information related to drug safety and efficacy for Risankizumab. Notably, the previous version's location details have been largely replaced or removed.SummaryDifference15%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check42 days agoChange DetectedThe webpage has updated its version from v2.16.9 to v2.16.11 and has removed several past dates from June 2024 while adding new dates in August 2025.SummaryDifference0.3%
- Check49 days agoChange DetectedThe web page has been updated to version 2.16.9, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.4%
Stay in the know with updates to Risankizumab in PsA Patients: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab in PsA Patients: Clinical Trial page.